MediPharm Labs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

MediPharm Labs şirketinin toplam hissedar öz sermayesi CA$45.0M ve toplam borcu CA$571.0K olup, bu da borç-öz sermaye oranını 1.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$55.8M ve CA$10.8M dir.

Anahtar bilgiler

1.3%

Borç/özkaynak oranı

CA$571.00k

Borç

Faiz karşılama oranı	n/a
Nakit	CA$13.43m
Eşitlik	CA$45.05m
Toplam yükümlülükler	CA$10.80m
Toplam varlıklar	CA$55.84m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MLZ 'nin kısa vadeli varlıkları ( CA$34.6M ) kısa vadeli yükümlülüklerini ( CA$10.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: MLZ şirketinin kısa vadeli varlıkları ( CA$34.6M ) uzun vadeli yükümlülüklerini ( CA$35.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MLZ şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: MLZ 'nin borç/öz sermaye oranı son 5 yılda 4.7% seviyesinden 1.3% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MLZ şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: MLZ serbest nakit akışı her yıl % { 25.2 2.4 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.

MediPharm Labs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 3Q 2023)

MediPharm Labs Corp. to Report Q3, 2024 Results on Nov 14, 2024

MediPharm Labs Corp. Announces Executive Changes

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.009 loss in 2Q 2023)

MediPharm Labs Corp. to Report Q2, 2024 Results on Aug 14, 2024

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

First quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.01 loss in 1Q 2023)

MediPharm Labs Corp. to Report Q1, 2024 Results on May 15, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: CA$0.04 loss per share (vs CA$0.11 loss in FY 2022)

MediPharm Labs Corp. to Report Q4, 2023 Results on Mar 27, 2024

Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 3Q 2022)

New minor risk - Profitability

Forecast to breakeven in 2024

MediPharm Labs Corp. to Report Q3, 2023 Results on Nov 14, 2023

Tilray Brands, Inc. (NasdaqGS:TLRY) acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. (TSX:LABS) for CAD 8.5 million.

MediPharm Labs Corp. Settles an Outstanding Claim for $9,000,000 with HEXO Corp

MediPharm Labs Corp. Launches New GMP Products to the Australian Medical Cannabis Market

Medipharm Labs Corp. Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

New major risk - Financial position

Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 2Q 2022)

MediPharm Labs Corp. to Report Q2, 2023 Results on Aug 14, 2023

MediPharm Labs Corp. Provides Update on US FDA Status

First quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 1Q 2022)

MediPharm Labs Corp. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

MediPharm Labs Corp. (TSX:LABS) entered into a definitive arrangement agreement to acquire VIVO Cannabis Inc. (TSX:VIVO) from directors and officers of VIVO and others for CAD 11.1 million.

Third quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.03 loss in 3Q 2021)

MediPharm Labs Corp. to Report Q3, 2022 Results on Nov 14, 2022

Onelife Botanicals Pty Ltd completed the acquisition of MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS).

Second quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.05 loss in 2Q 2021)

MediPharm Labs Corp. to Report Q2, 2022 Results on Aug 15, 2022

Onelife Botanicals Pty Ltd entered into an agreement to acquire MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS) for AUD 6.9 million.

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

First quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.07 loss in 1Q 2021)

MediPharm Labs Corp. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

MediPharm Labs Corp. Announces Management Changes

Medipharm Labs Corp Launches CBG and Water-Soluble Products

Full year 2021 earnings released: CA$0.22 loss per share (vs CA$0.48 loss in FY 2020)

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

Medipharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

CEO of Asia Pacific & Director recently sold €60k worth of stock

MediPharm Labs Expands CBN Portfolio with Two New Products

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.05 loss per share (vs CA$0.02 loss in 2Q 2020)

MediPharm Labs Corp. Receives Canadian GMP Pharmaceutical Drug Establishment Licence

Founder & Chairman of the Board recently sold €329k worth of stock

Independent Director recently bought €206k worth of stock

MediPharm Labs Launches High-CBD Wellness Oils in Quebec

First quarter 2021 earnings released: CA$0.07 loss per share (vs CA$0.13 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.48 loss per share (vs CA$0.014 profit in FY 2019)

MediPharm Labs Expands Distribution Revenue Footprint in Canada, Enters Growing Quebec Market Through New Supply Agreement

Independent Director recently bought €132k worth of stock

Medipharm Labs Corp. Announces Plan to Launch New Over-The-Counter Products

MediPharm Labs Corp. has completed a Composite Units Offering in the amount of CAD 29 million.

Interim Chief Financial Officer has left the company

New 90-day high: €0.57

MediPharm Labs Corp. Appoints Greg Hunter as Chief Financial Officer, Effective February 8, 2021

MediPharm Labs Appoints Warren Everitt to Board of Directors

MediPharm Labs Corp. Enters a Supply Agreement with Nova Scotia Liquor Corporation

New 90-day low: €0.32

MediPharm Labs Corp. Announces Executive Changes

Revenue misses expectations

Third quarter 2020 earnings released: CA$0.11 loss per share

New 90-day low: €0.47

MediPharm Labs Corp. Announces the Resignation of Bobby Kwon as Chief Financial Officer

MediPharm Labs Corp. First to Launch THC-Free, 99% Pure CBD Isolate Consumer Sized Crystal in Canada

MediPharm Labs Corp. to Report Q3, 2020 Results on Nov 16, 2020

STADA Enters Exclusive Medical Cannabis Partnership with Medipharm Labs Inc

MediPharm Labs Corp. (TSX:LABS) entered into a share sale and purchase agreement to acquire the remaining 20% stake in MediPharm Labs Australia Pty Ltd for approximately CAD 3.2 million.

MediPharm Labs Inc. Plans to Supply Premium, GMP-Certified Formulated Cannabis Oil to XLR8 BRAZIL